Compound Strengthens Bones and Muscles in Mice

An experimental compound, AP503, significantly strengthened bones in mice by activating the GPR133 receptor. This receptor boosts bone formation and slows bone loss. The same treatment has also been linked to stronger muscles. This suggests potential for combating age-related decline and osteoporosis.

Osteoporosis weakens bones and increases fracture risk. It affects millions globally. Current therapies have limitations and side effects. Researchers seek new biological targets for more effective bone preservation or rebuilding. Scientists at Leipzig University identified GPR133 as a key target. It appears to play an important role in maintaining strong bones.

GPR133 is an adhesion G protein-coupled receptor. These receptors are on cell surfaces and help cells respond to signals. When GPR133 is impaired by genetic changes, mice show early signs of bone density loss. This is similar to human osteoporosis. Stimulating GPR133 with AP503 increased bone strength in both healthy and osteoporotic mice. This indicates GPR133 is a valuable target for future osteoporosis treatments.

Activation of GPR133 encourages osteoblast activity and reduces osteoclast activity. Osteoblasts form new bone tissue. Osteoclasts remove old bone. This shifts the balance towards stronger, more durable bone. AP503 appears to mimic the natural activation of GPR133. This raises the possibility of using the compound to increase bone strength or restore weakened bone. This could include osteoporosis associated with menopause.

The findings may have broader implications. AP503 could affect more than the skeleton. An earlier study found AP503 activation also strengthens skeletal muscle. A treatment improving both bone and muscle strength would be relevant for older adults. They often experience declines in both tissues simultaneously. Stronger muscles support mobility and stability. Stronger bones reduce fracture vulnerability.